A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of INDV-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder
Latest Information Update: 01 Jun 2025
At a glance
- Drugs C4X 3256 (Primary)
- Indications Opioid-related disorders
- Focus Proof of concept; Therapeutic Use
- Sponsors Indivior
Most Recent Events
- 13 Jun 2024 Status changed from not yet recruiting to recruiting.
- 10 Jun 2024 According to Indivior PLC media release, first patient has been dosed in this study.
- 29 Apr 2024 New trial record